Sequential therapy in the treatment of osteoporosis

References

• National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
   Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008;86:129-43
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie L-G, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Czerwinski E, Stakkestad J, et al. Efficacy of monthly oral ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporosis Int 2009;20:S15
   Web of Science ®Google Scholar
• Black DM, Reid I, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. October 16, 2010
   Google Scholar
• Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
   PubMed Web of Science ®Google Scholar
• Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cummings SR, et al.; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82
   PubMed Web of Science ®Google Scholar
• Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008;15:495-501
   PubMed Web of Science ®Google Scholar
• FORTEO (teriparatide [rDNA origin]). Prescribing Information. Available at: http://pi.lilly.com/us/forteo-pi.pdf [Last accessed March 2011]
   Google Scholar
• Preotact. Summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/18249/SPC/Preotact/ [Last accessed March 2011]
   Google Scholar
• Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:869-83
   PubMed Web of Science ®Google Scholar
• Graeff C, Timm W, Nickelsen TN, et al. Monitoring teriparatide associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study. J Bone Miner Res 2007;22:1426-33
   PubMed Web of Science ®Google Scholar
• Zanchetta JR, Bogado C, Ferriti LJ, et al. Effects of LY333334 [recombinant parathyroid hormone (1-340)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone 2001;28(Suppl. 5):Abstract S86
   Google Scholar
• Hyldstrup L, Jorgensen JT, Gaich G. Assessment of the effects of ly333334 [recombinant parathyroid hormone (1-340)] on cortical bone using digital x-ray radiogrammetry. Bone 2001;28(Suppl. 5):Abstract S97
   Google Scholar
• Body JJ, Gaich GA, Scheele WH. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35
   PubMed Web of Science ®Google Scholar
• Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptides of type 1 collagen in postmenopausal osteoporosis. Clin Chem 2008;54:188-96
   PubMed Web of Science ®Google Scholar
• Borah B, Dufresne TE, Ritman EL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-52
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007;22:149-57
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41
   PubMed Web of Science ®Google Scholar
• Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003;88:1150-6
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53
   PubMed Web of Science ®Google Scholar
• Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23:1591-600
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Mosekilde L. Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone 1990;11:67-73
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
   PubMed Web of Science ®Google Scholar
• Black DM, Bouxsein ML, Palermo L, et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008;93:2166-72
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Rubin MR. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporosis Rep 2006;4:5-13
   PubMedGoogle Scholar
• Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34
   PubMed Web of Science ®Google Scholar
• Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726-36
   PubMed Web of Science ®Google Scholar
• Lyritis G, Marin F, Barker C, et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010;26:1799-807
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;11:566-75
   Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Neer R, Hayes A, Rao A, Finkelstein J. Effects of parathyroid hormone, alendronate or both on bone mineral density in osteoporotic postmenopausal women. J Bone Miner Res 2002;17S:135
   Google Scholar
• Cosman F. Zoledronic acid (Reclast) and teriparatide (Forteo). ASBMR: Meeting highlights 2009;34:632-3
   Google Scholar
• Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009;24:1110-15
   PubMed Web of Science ®Google Scholar
• Pleiner-Duxneuner J, Zwettler E, Paschalis E, et al. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009;84:159-70
   PubMed Web of Science ®Google Scholar
• NICE 2008 Guideline TA087. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. Available at: http://guidance.nice.org.uk/TA87 [Last accessed March 2011]
   Google Scholar
• Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:657-80
   Web of Science ®Google Scholar
• Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-93
   PubMed Web of Science ®Google Scholar
• Chevalier Y, Quek E, Borah B, et al. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 2010;46:41-8
   PubMed Web of Science ®Google Scholar
• Lawson MA, Xia Z, Barnett BL, et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res Part B Appl Biomater 2010;92:149-55
   PubMed Web of Science ®Google Scholar